KR20190129900A - 미토콘드리아 반응성 산소종(ros) 생산과 관련된 질환의 치료를 위한 데스메틸아네톨 트리티온 유도체 - Google Patents

미토콘드리아 반응성 산소종(ros) 생산과 관련된 질환의 치료를 위한 데스메틸아네톨 트리티온 유도체 Download PDF

Info

Publication number
KR20190129900A
KR20190129900A KR1020197028579A KR20197028579A KR20190129900A KR 20190129900 A KR20190129900 A KR 20190129900A KR 1020197028579 A KR1020197028579 A KR 1020197028579A KR 20197028579 A KR20197028579 A KR 20197028579A KR 20190129900 A KR20190129900 A KR 20190129900A
Authority
KR
South Korea
Prior art keywords
formula
ros
iia
day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197028579A
Other languages
English (en)
Korean (ko)
Inventor
필립 디올즈
프레드릭 마린
올리비에르 페티장
Original Assignee
오피2 드러그스
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
유니베르시떼 드 보르도
썽뜨르 오스삐딸리에 유니버시떼르 드 보르두
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오피2 드러그스, 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르), 유니베르시떼 드 보르도, 썽뜨르 오스삐딸리에 유니버시떼르 드 보르두 filed Critical 오피2 드러그스
Priority claimed from PCT/EP2018/055651 external-priority patent/WO2018162581A1/en
Publication of KR20190129900A publication Critical patent/KR20190129900A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197028579A 2017-03-07 2018-03-07 미토콘드리아 반응성 산소종(ros) 생산과 관련된 질환의 치료를 위한 데스메틸아네톨 트리티온 유도체 Ceased KR20190129900A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762467874P 2017-03-07 2017-03-07
US62/467,874 2017-03-07
EP17159691.9 2017-03-07
EP17159691 2017-03-07
PCT/EP2018/055651 WO2018162581A1 (en) 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Publications (1)

Publication Number Publication Date
KR20190129900A true KR20190129900A (ko) 2019-11-20

Family

ID=61628329

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028579A Ceased KR20190129900A (ko) 2017-03-07 2018-03-07 미토콘드리아 반응성 산소종(ros) 생산과 관련된 질환의 치료를 위한 데스메틸아네톨 트리티온 유도체

Country Status (10)

Country Link
US (1) US11484529B2 (https=)
EP (1) EP3592348A1 (https=)
JP (1) JP2020511450A (https=)
KR (1) KR20190129900A (https=)
CN (1) CN110662535A (https=)
AU (1) AU2018232799B2 (https=)
BR (1) BR112019018495A2 (https=)
CA (1) CA3055122A1 (https=)
IL (1) IL269127A (https=)
RU (1) RU2019131478A (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019336943A1 (en) * 2018-09-06 2021-03-18 OP2 Drugs Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
CN112546216B (zh) * 2020-11-20 2022-10-28 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用
WO2022123038A1 (en) * 2020-12-10 2022-06-16 OP2 Drugs Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
WO2022171265A1 (en) * 2021-02-09 2022-08-18 Boehringer Ingelheim International Gmbh Modulators of complex i
CN114414332B (zh) * 2022-01-05 2024-04-16 北京科技大学 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法
CN119185368A (zh) * 2024-09-26 2024-12-27 中南大学 具有线粒体序贯靶向能力的强抗氧化性纳米药物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
KR20030067935A (ko) 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
EP1288940B1 (en) * 2000-05-22 2009-12-02 Clarion Co., Ltd. Disk player
CN1355156A (zh) * 2000-11-27 2002-06-26 朱国和 含有造纸废料污泥的微生物菌肥及其制备方法
CN1244325C (zh) 2001-05-11 2006-03-08 成都国嘉联合制药有限公司 胆维他在制药中的应用
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20050182128A1 (en) 2002-02-13 2005-08-18 Stephen Lam Use of anethole dithiolethione in lung cancer chemoprevention
TW200640898A (en) 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
WO2008106640A1 (en) 2007-03-01 2008-09-04 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
CN102807557B (zh) * 2012-08-21 2015-02-04 苏州大学 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用
CN102961376B (zh) * 2012-11-06 2015-06-10 暨南大学 HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用
CN102961375B (zh) 2012-12-05 2015-01-14 苏州大学 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用

Also Published As

Publication number Publication date
IL269127A (en) 2019-11-28
US20210154175A1 (en) 2021-05-27
JP2020511450A (ja) 2020-04-16
RU2019131478A (ru) 2021-04-07
RU2019131478A3 (https=) 2021-07-09
US11484529B2 (en) 2022-11-01
AU2018232799B2 (en) 2021-11-25
AU2018232799A1 (en) 2019-10-03
CA3055122A1 (en) 2018-09-13
CN110662535A (zh) 2020-01-07
EP3592348A1 (en) 2020-01-15
BR112019018495A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
US11318113B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
KR20190129900A (ko) 미토콘드리아 반응성 산소종(ros) 생산과 관련된 질환의 치료를 위한 데스메틸아네톨 트리티온 유도체
JP7342183B2 (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
US9701631B2 (en) TIP60 inhibitors
CN102143744B (zh) 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途
JP2008110962A (ja) Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
KR20180073554A (ko) 중수소화 화합물 및 이의 용도
JP2023513797A (ja) Ｕｌｋ１／２阻害剤による単剤療法および併用療法
WO2018162581A1 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
EP3377061B1 (fr) Mirabégron pour le traitement de maladies rétiniennes
US10653668B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
WO2016068278A1 (ja) 水晶体硬化抑制剤
US5854287A (en) D-Propranolol metabolites useful for antioxidant activities
KR101896398B1 (ko) 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US20130084330A1 (en) Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient
US20220257570A1 (en) Calpain inhibitors and uses thereof for treating neurological disorders
US20260034103A1 (en) Compositions and methods for improving memory and cognition
US20210030719A1 (en) Grp94 inhibitors to treat steroid-induced ocular hypertensions and glaucomas
KR20180027157A (ko) 아멘토플라본을 포함하는 피지 과다분비 또는 지루성 습진의 억제 또는 개선용 조성물
CN119584967A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
JPWO2003000668A1 (ja) オキサ（チア）ゾリジン化合物、製造法および抗炎症薬
TW202033209A (zh) 抑制hrasq61l突變角質細胞活性及預防皮膚癌化之薄荷精油
JP2002080368A (ja) 抗炎症薬
KR20180119910A (ko) 피지 과다분비 또는 지루성 습진의 억제 또는 개선용 조성물
BR112015016433B1 (pt) Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210304

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230330

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230607

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230330

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I